For the screened targets, NAFLD suppressed NR1H4 and APOA1 expression was upregulated by YCHT treatment in both gene and protein levels (Fig. 8 G, H; Fig. 9). Here, APOA1 is linked to metabolic dysfunction-associated steatotic liver disease.